Sanofi SA has pledged to invest up to $2.2 billion in a new collaboration with Regeneron Pharmaceuticals Inc. in which the longtime partners will jointly develop and commercialize the programmed cell death protein-1 (PD-1) inhibitor REGN-2810 and other new immuno-oncology antibodies.